AbbVie (ABBV) Earnings Q1 2027
February 2, 2027 @ 4:05 pm - 5:05 pm
AbbVie (ABBV) Earnings Q1 2027
Next ABBV Quarterly Earnings: Tuesday, at 4:05 pm ET (9:05 pm London).
Date to be confirmed by the publisher; this is the scheduled date.
- Consensus
- Not yet published
- Prior
- Not yet published for this period
- Actual
- Pending
Updated
AbbVie (NYSE: ABBV) is scheduled to report quarterly earnings on Tuesday, February 2, 2027, with results due after the market closes at 4:05 pm ET (9:05 pm London). The Chicago-based pharmaceutical group, known for Humira, Skyrizi, Rinvoq and its Botox and aesthetics business, releases results through a press release and an accompanying investor call, both published via AbbVie’s investor relations site. Full schedule and background: AbbVie earnings dates.
The release matters to a wide range of investors because AbbVie is one of the largest components of US healthcare indices and a regular holding in dividend-focused and pension funds across the US, UK and Europe. Its results also offer a read on prescription drug pricing, biosimilar competition and the pace of growth in its post-Humira product lineup, all of which ripple into healthcare stocks and currency markets when guidance moves sharply.
What is AbbVie’s quarterly earnings report?
AbbVie’s quarterly earnings report is the company’s official disclosure of revenue, profit and guidance for the period, filed with the US Securities and Exchange Commission and published as a press release. It is prepared by AbbVie’s finance team and reviewed by independent auditors, then presented by the chief executive and chief financial officer on a live conference call with Wall Street analysts. The report breaks down sales by drug and therapeutic area, covering immunology treatments such as Skyrizi and Rinvoq, the neuroscience portfolio including Vraylar, oncology drugs, and the Allergan aesthetics business built around Botox Cosmetic and Juvederm.
Because AbbVie no longer has meaningful Humira revenue after losing US patent exclusivity, each report is also watched for how quickly newer drugs are offsetting that decline, a trend analysts have tracked closely since biosimilar competition intensified in 2023.
When is the report and how to follow it
The company has not yet formally confirmed the exact date for this release at the time of writing. AbbVie, like most large US pharmaceutical companies, typically reports its fourth-quarter and full-year results in the first week of February, so February 2, 2027 reflects that usual pattern rather than a confirmed company announcement. Investors should check AbbVie’s investor relations page closer to the date for the final confirmed time.
Results are released after the New York closing bell, with the press release posted first, followed roughly 30 minutes later by a live webcast and conference call where management takes analyst questions. The webcast is streamed free on AbbVie’s investor relations site and a replay is usually available within a few hours. London-based investors watching live should note the call typically falls in the evening, UK time, given the 5-hour gap to US Eastern time.
What to expect
A consensus forecast for this specific report has not yet been published, since detailed analyst estimates are typically compiled closer to the release date as the quarter closes. Historically, analysts surveyed by Reuters and Bloomberg build their forecasts around growth in Skyrizi and Rinvoq, margin trends in the aesthetics division, and the pace of share buybacks and dividend increases, all factors likely to shape commentary again this time.
AbbVie’s most recent full-year results, covering 2025, showed adjusted diluted earnings per share of $10.00, a decrease of 1.2 percent versus 2024, according to the company’s fourth-quarter and full-year 2025 press release. For the first quarter of 2026, AbbVie reported adjusted diluted earnings per share of $2.65, an increase of 7.7 percent year on year, according to the company’s first-quarter 2026 results statement. Heading into the third quarter of 2026, AbbVie had guided to adjusted diluted earnings per share of between $3.84 and $3.88, as set out in a subsequent regulatory filing.
Analysts typically focus on three things in AbbVie’s reports: the growth rate of Skyrizi and Rinvoq combined, which have become the company’s main growth engines since Humira’s decline; margin trends in the aesthetics unit, which is sensitive to discretionary consumer spending in the US and China; and full-year guidance, since any change to the outlook tends to move the share price more than the headline quarterly numbers themselves. A verified table of the prior four quarters’ revenue and earnings per share against estimates is not included here, as not all of the relevant figures for the quarters immediately preceding this release had been independently confirmed via AbbVie’s investor relations materials at the time of writing. Readers wanting the full run of historical results can find them directly on AbbVie’s investor relations site.
What the outcome could mean
| Scenario | Likely market read | Plain-English meaning |
|---|---|---|
| Beat on earnings and raised guidance | Shares likely rise, healthcare sector sentiment improves | AbbVie’s newer drugs and aesthetics business are growing faster than expected, easing concerns about life after Humira |
| In line with prior guidance | Limited share price reaction, focus shifts to forward commentary | The business is performing broadly as management predicted, with no major surprises for investors |
| Miss or guidance cut | Shares likely fall, pressure on wider pharmaceutical and healthcare indices | Growth from key drugs or weaker consumer demand for aesthetics procedures is not covering the loss of Humira sales |
What It Means for Your Money
AbbVie is a major constituent of US healthcare exchange-traded funds and a common holding in workplace pensions and index funds, including many default pension funds held by UK and European savers through global equity trackers. A strong or weak earnings report can therefore move the value of retirement savings even for people who have never bought an individual share. The company is also one of the largest dividend payers in the pharmaceutical sector, so changes to its payout or buyback plans can affect income-focused funds that many retirees rely on.
For consumers, AbbVie’s results offer an indirect signal about prescription drug costs and demand for cosmetic procedures such as Botox, both of which are sensitive to household budgets. A weaker aesthetics result can hint at softer discretionary spending more broadly, something economists sometimes read as an early sign of consumer caution. Currency moves are a secondary factor: AbbVie earns revenue globally, so a stronger or weaker dollar against the pound and euro can flatter or dent reported growth, even when underlying drug sales are stable, which is one reason currency-hedged versions of US healthcare funds exist for international investors.
Related events
- Other major US pharmaceutical earnings reported around the same week, including Pfizer and Merck
- US Food and Drug Administration decisions affecting AbbVie’s pipeline drugs
- Broader US healthcare sector earnings season coverage
Frequently Asked Questions
What time does AbbVie report earnings on February 2, 2027?
AbbVie is expected to report after the market closes, at 4:05 pm ET, which is 9:05 pm in London, though the company has not yet formally confirmed the exact time for this release.
Is the February 2, 2027 date confirmed by AbbVie?
No, the date is an estimate based on AbbVie’s usual pattern of reporting full-year and fourth-quarter results in the first week of February. The confirmed date is typically announced a few weeks in advance on the company’s investor relations site.
Where can I watch AbbVie’s earnings call live?
The call is streamed free via a webcast link on AbbVie’s investor relations website, with a replay usually posted within a few hours of the live event.
What is the consensus forecast for this report?
A consensus forecast had not yet been published at the time of writing, as analyst estimates for this specific quarter are typically compiled closer to the release date.
Why do AbbVie’s results affect my pension even if I do not own the shares directly?
Many pension funds and index trackers hold AbbVie as part of broad US healthcare or S&P 500 exposure, so a significant move in its share price after earnings can have a small but real effect on the value of those funds.